Lymphoma, Mantle-Cell: all 810 studies
Page 2 of 9. Open to participants first (149), then studies with results posted, then the rest; newest registration first within each.
- A Study of PEP07 (Checkpoint Kinase 1 Inhibitor) in Patients With Advanced CancerRecruitingNCT05659732Phase 1
- A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell MalignanciesRecruitingNCT05643742Phase 1/2
- Implanted Loop Recorders for Detection and Management of Arrhythmia With Bruton Tyrosine Kinase InhibitorsRecruitingNCT05643235Not applicable
- Zanubrutinib Plus Rituximab for Patients With Indolent Mantle Cell LymphomaRecruitingNCT05635162Phase 2
- AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin LymphomaRecruitingNCT05602363Phase 1
- Study of SGR-1505 in Mature B-Cell NeoplasmsRecruitingNCT05544019Phase 1
- Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) PatientsRecruitingNCT05529069Phase 2
- A Clinical Study of Hanlikang and BTK Inhibitors in the Treatment of Newly Diagnosed Mantle Cell LymphomaRecruitingNCT05506410
- Zanubrutinib-rituximab(ZR) in Patients With Newly Diagnosed Untreated Mantle Cell LymphomaRecruitingNCT05504603Phase 2
- Zanubrutinib in the Treatment of Recurrent Refractory Mantle Cell LymphomaRecruitingNCT05486013
- A Study of RD14-01 in Patients With Relapsed or Refractory B Cell Non-Hodgkin LymphomaRecruitingNCT05444322Early Phase 1
- Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin LymphomaRecruitingNCT05432635Phase 1
- BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHLRecruitingNCT05370430Phase 1
- IKS03 in Patients With Advanced B Cell Non-Hodgkin LymphomasRecruitingNCT05365659Phase 1
- Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-DegraderRecruitingNCT05294731Phase 1/2
- Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic LeukemiaRecruitingNCT05281809Phase 2
- Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR TherapyRecruitingNCT05255354
- A Study Comparing Rituximab/Bendamustin(RB) Alternating With Rituximab/Bendamustin/Cytarabin(RBAC) With RB Therapy in Elderly Patients With Mentle Cell LymphomaRecruitingNCT05245656Phase 2
- A Study of NX-5948 in Adults With Relapsed/Refractory B-cell MalignanciesRecruitingNCT05131022Phase 1
- Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL PatientsRecruitingNCT05098613Phase 1
- Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell LymphomaRecruitingNCT05020392Phase 3
- A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell MalignanciesRecruitingNCT05006716Phase 1/2
- Study of PV in Combination With Bendamustine and Rituximab for Patients With R/R MCLNot yet recruitingNCT04913103Phase 2
- Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin LymphomasRecruitingNCT04883437Phase 2
- Avo In R/R And Previously Untreated MCLRecruitingNCT04855695Phase 1/2
- A Study of NX-2127 in Adults With Relapsed/Refractory B-cell MalignanciesRecruitingNCT04830137Phase 1
- DALY II USA/ MB-CART2019.1 for DLBCLRecruitingNCT04792489Phase 2
- Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.RecruitingNCT04775745Phase 1
- Zanubrutinib-based Induction and Maintenance Therapy in Young and Fit Patients With Untreated Mantle Cell LymphomaRecruitingNCT04736914Phase 2
- Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin LymphomaRecruitingNCT04545762Phase 1
- Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin LymphomaRecruitingNCT04491370Phase 1/2
- CONFIRM: Magnetic Resonance Guided Radiation TherapyRecruitingNCT04368702Not applicable
- The OPAL Study: AVM0703 for Treatment of Lymphoid MalignanciesRecruitingNCT04329728Phase 1/2
- Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.RecruitingNCT04223765Phase 1
- Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological MalignanciesRecruitingNCT04195633Phase 2
- CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell MalignanciesRecruitingNCT04186520Phase 1/2
- REal World Data in LYmphoma and Survival in AdultsRecruitingNCT03869619
- Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CARRecruitingNCT03676504Phase 1/2
- Ixazomib Maintenance in Patients With Newly Diagnosed Mantle Cell Lymphoma(MCL)RecruitingNCT03616782Phase 2
- Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell LymphomaRecruitingNCT03523975Phase 1/2
- Evaluation of Human Immune Responses Vaccination in Patients With LymphomaRecruitingNCT03501576
- SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and RegistryRecruitingNCT03452774
- Long-term Follow-up Study of Patients Receiving CAR-T CellsRecruitingNCT03375619
- Myeloablative Allo HSCT With Related or Unrelated Donor for Heme DisordersRecruitingNCT03314974Phase 2
- Liquid Biopsy in Mature B-cell TumorsRecruitingNCT03280394
- Auto Stem Cell Transplant for Lymphoma PatientsRecruitingNCT03125642Phase 2
- ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell LymphomaRecruitingNCT02858258Phase 3
- Registry of Older Patients With CancerRecruitingNCT01137825
- Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic CancerRecruitingNCT01137643
- Adaptive Bridging RT in R/R B-cell Lymphoma (Pre-CAR T)CompletedNCT06004167Not applicableResults posted
- A Study of Tafasitamab and Lenalidomide in People With Mantle Cell LymphomaTerminatedNCT05788289Phase 2Results posted
- A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell LymphomaCompletedNCT05564052Phase 2Results posted
- Study of Sonrotoclax (BGB-11417) Monotherapy in Participants With Relapsed or Refractory Mantle Cell LymphomaActive, not recruitingNCT05471843Phase 1/2Results posted
- Phase II Trial of Venetoclax and Rituximab as Initial Therapy in Older Patients With Mantle Cell LymphomaTerminatedNCT05025423Phase 2Results posted
- Acalabrutinib Study in Indian Patients With Chronic Lymphocytic Leukaemia & Relapsed and Refractory Mantle Cell LymphomaCompletedNCT04930536Phase 4Results posted
- Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3)CompletedNCT04880434Phase 2Results posted
- A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia)CompletedNCT04849416Phase 2Results posted
- Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell LymphomaActive, not recruitingNCT04783415Phase 2Results posted
- Clinical Trial of Ublituximab and Umbralisib With CHOP (U2-CHOP) Followed by U2 Maintenance (U2-CHOP-U2) in Previously Untreated Mantle Cell Lymphoma (MCL)TerminatedNCT04692155Phase 1/2Results posted
- Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell LymphomaTerminatedNCT04659044Phase 2Results posted
- Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell LymphomaActive, not recruitingNCT04626791Phase 2Results posted
- Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell MalignanciesCompletedNCT04599634Phase 1Results posted
- Study to Assess Effect of Oral Venetoclax Tablet in Combination With Oral Ibrutinib Capsule on Best Overall Response of Complete Response in Adult Japanese Participants With Relapsed/Refractory Mantle Cell LymphomaCompletedNCT04477486Phase 2Results posted
- APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL)TerminatedNCT04419389Phase 1/2Results posted
- Treatment With Acalabrutinib Post Blood or Marrow Transplantation in Subjects With Mantle Cell LymphomaCompletedNCT04402138Phase 2Results posted
- First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin LymphomasTerminatedNCT04358458Phase 1/2Results posted
- Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and TislelizumabCompletedNCT04282018Phase 1/2Results posted
- Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic MalignanciesCompletedNCT04205409Phase 2Results posted
- Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic MalignanciesCompletedNCT04191187Phase 2Results posted
- Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell LymphomaTerminatedNCT04047797Phase 2Results posted
- Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell MalignanciesActive, not recruitingNCT03932331Phase 1/2Results posted
- A Study of Copanlisib and Ibrutinib in Mantle Cell LymphomaCompletedNCT03877055Phase 1/2Results posted
- Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell LymphomaActive, not recruitingNCT03872180Phase 2Results posted
- Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCLActive, not recruitingNCT03863184Phase 2Results posted
- Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of AgeCompletedNCT03834688Phase 2Results posted
- Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular LymphomaTerminatedNCT03685344Phase 1Results posted
- Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell LymphomaTerminatedNCT03684694Phase 1/2Results posted
- Trial Evaluating MGTA-456 in Patients With High-Risk MalignancyActive, not recruitingNCT03674411Phase 2Results posted
- Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell LymphomaCompletedNCT03623373Phase 2Results posted
- Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular LymphomaTerminatedNCT03571828Phase 1Results posted
- A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell LymphomaCompletedNCT03323151Phase 1/2Results posted
- Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell LymphomaTerminatedNCT03311126Phase 2Results posted
- A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin LymphomasActive, not recruitingNCT03277729Phase 1/2Results posted
- Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic MalignanciesTerminatedNCT03272633Early Phase 1Results posted
- Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell TransplantationTerminatedNCT03246906Phase 2Results posted
- A Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a Bruton's Tyrosine Kinase (BTK) InhibitorCompletedNCT03235544Phase 2Results posted
- Study to Evaluate Efficacy and Safety of BGB-3111 in Participants With Relapsed or Refractory Mantle Cell Lymphoma (MCL)CompletedNCT03206970Phase 2Results posted
- A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p DeletionCompletedNCT03190330Phase 4Results posted
- Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived MalignanciesTerminatedNCT03151057Phase 1Results posted
- High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell TransplantCompletedNCT03128359Phase 2Results posted
- Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL)CompletedNCT03112174Phase 3Results posted
- A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid MalignanciesCompletedNCT03088878Phase 1/2Results posted
- Phase I/Ib Study of Nivolumab & Veliparib in Patients With Advanced Solid Tumors & LymphomaCompletedNCT03061188Phase 1Results posted
- Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin LymphomaCompletedNCT03035331Phase 1/2Results posted
- Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor PatientsCompletedNCT03028103Phase 1Results posted
- Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's LymphomaCompletedNCT03019640Phase 2Results posted
- Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin LymphomaCompletedNCT03010358Phase 1/2Results posted
- Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme MalignanciesTerminatedNCT02991898Phase 2Results posted
- TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular LymphomaCompletedNCT02927964Phase 1/2Results posted
- Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant PatientsTerminatedNCT02877082Phase 2Results posted